Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Linezolid-induced peripheral neuropathy in a patient with multidrug-resistant pulmonary tuberculosis: a case report and comprehensive literature review.

Neurologia croatica : glasilo Udruzenja neurologa Jugoslavije = official journal of Yugoslav Neurological Association·2026
Same author

Application of a clinical scale for predicting Aβ-positivity in a multicentre Canadian dementia cohort: A necessity in the era of amyloid targeting treatment.

Journal of the neurological sciences·2026
Same author

Selective molecular and network architecture features underlie brain cortical atrophy in dementia with Lewy bodies.

Journal of biomedical science·2026
Same author

Biases and consistency of different assay methods for neurological biomarkers using Quanterix single-molecule-array technology: A secondary analysis method comparison study.

NeuroMarkers·2026
Same author

Simoa and MSD platforms show analytical discordance but comparable diagnostic performance for GFAP, NF-L, and T-tau in adolescent concussion.

Scientific reports·2026
Same author

Examining the effects of alcohol use on verbal memory processes in older adults with mild cognitive impairment.

Journal of Alzheimer's disease : JAD·2026
Same journal

Unveiling the procoagulant state in Alzheimer's disease: A novel PET imaging strategy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Estimated labor market outcomes of people progressing from preclinical to early-stage Alzheimer's disease in the United States.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Amyloid exacerbates tau and alpha-synuclein pathologies, behavioral impairments, and neuroinflammation in a mixed dementia model.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
查看所有相关文章

相关实验视频

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

生物标志物 生物标志物

Durjoy Lahiri1,2,3, Jennifer G Cooper4, Bruna Seixas Lima5,6

  • 1Department of Medicine, Queen's University, Kingston, ON, Canada.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
PubMed
概括
此摘要是机器生成的。

没有粉样质斑块的阿尔茨海默症患者表现出鲜明的血液生物标志物概况. 化陶 (p-tau),GFAP和NfL水平在粉样蛋白阴性个体中升高,这表明有不同的潜在病理.

更多相关视频

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

相关实验视频

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

科学领域:

  • 神经学 神经学
  • 生物标志物发现发现
  • 神经退行性疾病 神经退行性疾病

背景情况:

  • 很大一部分阿尔茨海默氏综合征患者缺乏大脑粉样质斑块.
  • 粉样蛋白阳性 (Aβ+) 和粉样蛋白阴性 (Aβ-) 个体之间的病理差异尚未得到充分理解.
  • 基于血液的生物标志物可以阐明Aβ-阿尔茨海默氏症的病理生理学.

研究的目的:

  • 为了在临床阿尔茨海默症中比较Aβ-和Aβ+亚组之间的基于血液的生物标志物.
  • 识别潜在的诊断标记,以区分阿尔茨海默氏症的表型.

主要方法:

  • 对抗粉样蛋白临床试验中患者的回顾性图表审查.
  • 粉样蛋白-β (Aβ) 状态通过脑脊液分析或PET成像确定.
  • 使用 Quanterix Simoa HD-X 进行血分析,检测p-tau 181,p-tau 217,GFAP,NfL 和 TDP-43.

主要成果:

  • 在Aβ+ (n=25) 和Aβ- (n=20) 组之间没有显著的人口或认知差异.
  • 在Aβ+组中,p-tau 181,p-tau 217,GFAP和NfL度显著更高.
  • 虽然Aβ-组的TDP-43度显著更高,但在统计学上并不显著.

结论:

  • 鲜明的血液生物标志物概况区分Aβ+和Aβ-阿尔茨海默氏综合征患者.
  • 这些发现提供了对粉样蛋白阴性阿尔茨海默氏症亚组的病理生理学的见解.
  • 血液生物标志物为了解阿尔茨海默氏症异质性的潜在途径提供了机会.